Startup valuation and pre-diligence checks — vc-scan
The Podium
which idea more than one company is chasing6 Aug – 3 Nov
Chips built for AI
Firmus, Tenstorrent, FuriosaAI, Infinigence AI, EUCLYD, Moffett AI, Nano-core Chip, Salience Labs, Callosum, Ubitium, Photon Bridge, Velatir, MintNeuro, Solinide, Embedd, HexSeed Technology, Groq, SUNMMIO
$6.1bn reported
AI agents doing the work
Butterfly Effect, Ema, Vesta, Restate, Eagle Cloud, Ghost, Zeliq, Primo, Opply, 50skills, Shamrock AI, Granite, Kontext, Reduck, Cygrid, Itoflow, Aisot Technologies
$706.9m reported
Grid & energy storage
Nexeon, Amber, Yuma Energy, MP Space, Certain Energy, Octave.energy, Neu Battery Materials, Boldr, Metris Energy, Rebaba, Furo, Econili, AcouBatt
$297.4m reported
The Intake
who raised · what they're building- Other B2B Software3116%$827.3m
- Robotics2111%$816.8m
- Fintech1910%$269.6m
- Semiconductors137%$2.7bn
- AI137%$1.1bn
- 3 NovEconili$2m(reported)
Recycles used batteries at plants in Malaysia to recover the materials inside them.
- 3 NovGranter€1.6m(reported)
Software that helps companies find and apply for European public funding programmes.
- 3 NovMoffett AI¥1bn(reported)
Designs chips that run already-trained AI models, cutting the work each answer needs by skipping empty calculations.
Dry Powder
who's writing cheques542 firms backed a startup in the last 90 days. 9 in 10 did it once.
firms named in the rounds we collected · 55% of rounds name an investor · names collected since 7 Aug
- 5 companiesSeedcamp·Sequoia·Y Combinator
- 4 companiesBalderton Capital·High-Tech Gründerfonds·IDG Capital
- 1 company477
- 2 companies52
- 3 companies7
- 4+ companies6
The Diligence Desk
Who's writing cheques: the firms backing the most startups, to 30 Oct
Which investors are actually backing startups right now, what they back, and who just started.
read it→Which investors are actually backing startups right now, what they back, and who just started.
We ran one real company through every check we have. Here is what the public record shows, and what we would ask.
Drug start-ups are valued on the odds their medicine survives its trials, not on revenue. Here's how that works.
The four sectors everyone is excited about turn out to be one supply chain. Most of the money in them was four cheques.
We counted every new US venture fund filing for three months. Most of them are not funds.
Everything above came out of a free public record.
The same check runs on your company in about a minute — overdue filings, charges still on the register, an ownership record that doesn't match your deck. Better you see it first.
run it on your own company→